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Still Struggling for the Right Answer*Clive Rosendorff, MD, PHDI n the early 1970s, the National Heart, Lung, andBlood Institute established the National HighBlood Pressure Education Program, which was
charged with providing recommendations for the
diagnosis and management of hypertension. This
resulted in the appearance in 1977 of the ﬁrst report
of the Joint National Committee (JNC) on Detection,
Evaluation, and Treatment of High Blood Pressure
(1), whose unwieldy title was abbreviated to JNC-1.
In this report, only those individuals with a diastolic
blood pressure (BP) of $120 mm Hg were recom-
mended for prompt evaluation and treatment. We
have come a long way since then, and that is in no
small way due to the diligence of the authors of
the successive iterations of the JNC reports, appear-
ing at approximately 3-year intervals, to summarize
and codify the evolving state of knowledge in this
ﬁeld.
In 2003, JNC-7 (2) established BP goals of <140/90
mm Hg for the general population and <130/80
mm Hg for patients with diabetes and/or chronic
kidney disease (CKD). Soon thereafter, the JNC-8
committee was constituted, but all was not smooth
sailing. The National Heart, Lung, and Blood Institute
decided that it no longer wished to be in the business
of guidelines, and no other organizations rushed in to
provide alternative sponsorship to the previously
organized writing committee. The result was that the
writing committee of what was to have been JNC-8,*Editorials published in the Journal of the American College of Cardiology
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recommendations anyway. This appeared in 2014 (3),
11 years after JNC-7.
The “JNC-8” panel recommendations were con-
ﬁned to 3 questions: the level of BP at which treat-
ment should be initiated, the BP goal of therapy, and
the selection of the appropriate drug therapy. The
JNC-8 panel recommendations were claimed to be
based on a systematic review of selected randomized
controlled trials and, therefore, entirely “evidence-
based.” However, a shadow fell between that high
ideal and the reality. Of the 10 recommendations for
hypertension management, only 4 were based on
randomized controlled trials evidence, and the re-
maining 6 were based on “expert opinion.”
Be that as it may, the document is a useful and
timely state-of-the-art review, and was generally
received as such, with some notable exceptions.
These were the decisions to abandon the lower BP
target, <130/80 mm Hg, for those patients with dia-
betes and CKD in favor of <140/90 mm Hg, and also
the recommendation to increase the target systolic BP
from 140 to 150 mm Hg in persons age 60 years or
older without diabetes mellitus or CKD.
The recommendation of a higher BP target for the
“over-60s” contradicts the avalanche of hypertension
guidelines that appeared in 2013 to 2014, including
those from the European Society of Hypertension and
the European Society of Cardiology (4); the American
Heart Association, American College of Cardiology,
and Centers for Disease Control and Prevention (5);
and the American Society of Hypertension and the
International Society of Hypertension (6), as well as
others 1 to 2 years earlier (7,8), all of which supported
a treatment goal of <140/90 mm Hg in all patients
except, in some cases, patients older than age 80
years, where the rules were relaxed slightly. This
leaves as a point of contention the huge number of
hypertensive patients between the ages of 60 and 80
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2205years, and contentious it has been. So much so that 5
members of the “JNC-8” Writing Committee took the
unprecedented step of publishing a “minority report”
(9), dissociating themselves from the JNC-8 panel
recommendations on relaxed BP goals for those older
than 60 years of age.
Authors of the minority report reminded us that it
is undisputed that lowering BP improves cardiovas-
cular outcomes, and that the JNC-8 panel had failed
to identify evidence of harm of treatment to any
particular target. The studies included in the JNC-8
panel recommendations, which failed to show a
beneﬁt of <140 mm Hg versus a higher goal, were
underpowered to do so, and 1 study that did show
beneﬁt was excluded by the very rigorous JNC-8
panel criteria.
The main studies, which were quoted by JNC-8 to
show no beneﬁt of the lower BP goal, were the JATOS
(Japanese Trial to Assess Optimal Systolic Blood
Pressure in Elderly Hypertensive Patients) (10) and
VALISH (Valsartan in Elderly Isolated Systolic Hy-
pertension Study) (11). Neither included patients in
the age 60 to 65 year range (JATOS age 65 to 85 years,
VALISH age 70 to 84 years); JATOS had a target BP
value of 140 to 159 mm Hg for the “moderate” BP
control arm, different from the 140 to 150 mm Hg
range of the JNC-8 panel recommendations; in both
studies the observed rate of cardiovascular events
was much lower than predicted, suggesting that the
studies were underpowered to show beneﬁt of a
target of <140 mm Hg; and the studies were of rela-
tively short duration (JATOS 2 years, VALISH 2.85
years). Also, both were in a Japanese cohort, which
could limit the generalizability of the ﬁndings. The
minority report then predicted that “the higher SBP
goal in individuals aged 60 years or older may reverse
the decades-long decline in CVD, especially stroke
mortality” and might partially undo “the remarkable
progress in reducing cardiovascular mortality in
Americans older than 60 years” (9).SEE PAGE 2196We now have some quantiﬁcation of that risk. In
this issue of the Journal, Borden et al. (12) have
utilized the National Cardiovascular Data Registry’s
Practice Innovation and Clinical Excellence Registry
as a data source to assess the potential impact of the
JNC-8 panel recommendations to increase the BP
targets for patients age 60 years and older, as well
as those with diabetes. They did this by comparing
the number of individuals, out of the total cohort of
1,118,253 patients, who were eligible for antihyper-
tensive treatment according to the JNC-7 criteria(BP >140/90 mm Hg, and >130/80 mm Hg for those
with diabetes) versus the JNC-8 panel recommen-
dations (BP >140/90 mm Hg for all patients <60
years of age, and >150/90 mm Hg for those older
than age 60 years who do not have diabetes or
CKD). The study found that 14.6% of those patients
who would have been eligible for initiation or
intensiﬁcation of antihypertensive therapy according
to the 2003 JNC-7 guideline goals would not be
treated with the new JNC-8 panel recommendations.
This is similar to a recent national population anal-
ysis reported by Navar-Boggan et al. (13) that esti-
mated 15.9%.
Borden et al. (12) found that those patients for
whom the recommendations had changed and who
would no longer be eligible for initiation or inten-
siﬁcation of treatment had an average 10-year risk
of myocardial infarction or death of 8.5%, and
when including stroke risk, of 28%. This number
was estimated to be reduced to approximately 19%
if those patients were treated to the JNC-7 guideline
goals, equivalent to a number-needed-to-treat, for
more than 10 years, of 10 to 11 patients to prevent 1
cardiovascular event. That this is not trivial is
brought home by the authors’ statement: “Using
these data about the patients age 60 years and
older, treatment of the more than 80,000 older
patients in our study population affected by the
change in targets to a systolic blood pressure goal of
140 mm Hg could potentially avert approximately
8,000 cardiovascular events over 10 years” (12). On
a national scale, the analysis by Navar-Boggan et al.
(13) estimates that, in the United States, 13.5 million
patients with hypertension who were previously
eligible to be treated under the JNC-7 guideline
goals would not be treated under the JNC-8 panel
recommendations.
That is the unintended consequence of what is
otherwise a thoughtful and useful set of recommen-
dations from the JNC-8 Writing Committee for the
management of hypertension. We do not know how
practice patterns will change based on the JNC-8
panel recommendations, but it will be important to
monitor these patterns; to follow BP control on a
population basis, especially in those patients older
than age 60 years and those with diabetes; and to
follow any consequent changes in cardiovascular
morbidity and mortality in these very large and
growing segments of our population.
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